267 related articles for article (PubMed ID: 24419756)
1. Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
Ghiringhelli F; Bichard D; Limat S; Lorgis V; Vincent J; Borg C; Berthou J; Orry D; Ortega-Deballon P; Lakkis Z; Facy O; Heyd B; Rat P; Nerich V; Ladoire S
Ann Surg Oncol; 2014 May; 21(5):1632-40. PubMed ID: 24419756
[TBL] [Abstract][Full Text] [Related]
2. Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
Figueras J; Lopez-Ben S; Alsina M; Soriano J; Hernandez-Yagüe X; Albiol M; Guardeño R; Codina-Barreras A; Queralt B
Clin Transl Oncol; 2013 Jun; 15(6):460-6. PubMed ID: 23143951
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
Bennouna J; Borg C; Delord JP; Husseini F; Trillet-Lenoir V; Faroux R; François E; Ychou M; Goldwasser F; Bouché O; Senellart H; Kraemer S; Douillard JY
Clin Colorectal Cancer; 2012 Mar; 11(1):38-44. PubMed ID: 21803002
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
Dirican A; Varol U; Kucukzeybek Y; Alacacioglu A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Yildiz Y; Koyuncu B; Coban E; Tarhan MO
Asian Pac J Cancer Prev; 2014; 15(12):4781-6. PubMed ID: 24998541
[TBL] [Abstract][Full Text] [Related]
5. Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
Shitara K; Yuki S; Yamazaki K; Naito Y; Fukushima H; Komatsu Y; Yasui H; Takano T; Muro K
J Cancer Res Clin Oncol; 2013 Apr; 139(4):595-603. PubMed ID: 23250506
[TBL] [Abstract][Full Text] [Related]
6. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Scoggins CR; Campbell ML; Landry CS; Slomiany BA; Woodall CE; McMasters KM; Martin RC
Ann Surg Oncol; 2009 Jan; 16(1):35-41. PubMed ID: 18987915
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
Modest DP; Reinacher-Schick A; Stintzing S; Giessen C; Tannapfel A; Laubender RP; Brodowicz T; Knittelfelder R; Vrbanec D; Schmiegel W; Heinemann V; Zielinski CC
Anticancer Drugs; 2012 Jul; 23(6):666-73. PubMed ID: 22441566
[TBL] [Abstract][Full Text] [Related]
8. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
Cetin B; Kaplan MA; Berk V; Tufan G; Benekli M; Isikdogan A; Ozkan M; Coskun U; Buyukberber S
Jpn J Clin Oncol; 2013 Jan; 43(1):28-32. PubMed ID: 23107836
[TBL] [Abstract][Full Text] [Related]
10. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
[TBL] [Abstract][Full Text] [Related]
11. The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
Popov I; Milicević M; Radosević-Jelić Lj
Acta Chir Iugosl; 2008; 55(4):11-6. PubMed ID: 19245134
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Schmiegel W; Reinacher-Schick A; Arnold D; Kubicka S; Freier W; Dietrich G; Geißler M; Hegewisch-Becker S; Tannapfel A; Pohl M; Hinke A; Schmoll HJ; Graeven U
Ann Oncol; 2013 Jun; 24(6):1580-7. PubMed ID: 23463625
[TBL] [Abstract][Full Text] [Related]
13. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
Hochster HS; Hart LL; Ramanathan RK; Childs BH; Hainsworth JD; Cohn AL; Wong L; Fehrenbacher L; Abubakr Y; Saif MW; Schwartzberg L; Hedrick E
J Clin Oncol; 2008 Jul; 26(21):3523-9. PubMed ID: 18640933
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Van Cutsem E; Rivera F; Berry S; Kretzschmar A; Michael M; DiBartolomeo M; Mazier MA; Canon JL; Georgoulias V; Peeters M; Bridgewater J; Cunningham D;
Ann Oncol; 2009 Nov; 20(11):1842-7. PubMed ID: 19406901
[TBL] [Abstract][Full Text] [Related]
16. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Kim S; Dobi E; Jary M; Monnien F; Curtit E; Nguyen T; Lakkis Z; Heyd B; Fratte S; Cléau D; Lamfichekh N; Nerich V; Guiu B; Demarchi M; Borg C
BMC Cancer; 2013 Dec; 13():611. PubMed ID: 24373251
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Hong YS; Lee SS; Kim KP; Lee JL; Kang YK; Shin SJ; Ahn JB; Jung KH; Im SA; Kim TY; Kim JH; Park YS; Kim TW
Am J Clin Oncol; 2014 Feb; 37(1):19-23. PubMed ID: 23111359
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
[TBL] [Abstract][Full Text] [Related]
19. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
Di Bartolomeo M; Ciarlo A; Bertolini A; Barni S; Verusio C; Aitini E; Pietrantonio F; Iacovelli R; Dotti KF; Maggi C; Perrone F; Bajetta E
Eur J Cancer; 2015 Mar; 51(4):473-481. PubMed ID: 25637137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
